The present inventors investigated the effects of anti-IL-6 receptorantibodies onimproving the condition of infarcted areas in myocardial infarction, and onsuppressing leftventricular remodeling after myocardial infarction. As a result, theadministration of anti-IL-6receptor antibodies significantly suppressed the increase of MPO activity inthe infarcted areaand suppressed myocardial MCP-1 expression in both the infarcted area and thenon-infarctedarea. Furthermore, echocardiography and histological examinations revealedthat cardiachypertrophy is also suppressed.
